Triple Negative Breast Cancer Clinical Trials

68 studies are recruiting for triple negative breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beverly Hills Cancer Center, Beverly Hills, California

   Locations

   39 in total

   Run by

   SystImmune Inc.

   See if you can join NCT05983432 on ClinicalTrials.gov

2. Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

   The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Stony Brook Breast Center, Stony Brook, New York

   Run by

   Alison Stopeck

   See if you can join NCT06220214 on ClinicalTrials.gov

3. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

   A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dren Investigational Site, Denver, Colorado

   Locations

   10 in total

   Run by

   Dren Bio

   See if you can join NCT06999187 on ClinicalTrials.gov

4. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

   A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   St Vincent's Hospital, Darlinghurst, New South Wales

   Locations

   16 in total

   Run by

   OncoNano Medicine, Inc.

   See if you can join NCT06022029 on ClinicalTrials.gov

5. Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

   This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06238921 on ClinicalTrials.gov

6. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

   This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   14 in total

   Run by

   Volastra Therapeutics, Inc.

   See if you can join NCT05902988 on ClinicalTrials.gov

7. Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

   The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immunotherapy before surgery. Pathologic complete (pCR) response means that no cancer in the breast is s…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT07066189 on ClinicalTrials.gov

8. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

   The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   10 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT06682793 on ClinicalTrials.gov

9. A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

   This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   LSU Health Sciences Center, Shreveport, Louisiana

   Run by

   Pure Biologics S.A.

   See if you can join NCT06700070 on ClinicalTrials.gov

10. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sharp Memorial Hospital, San Diego, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

11. A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

    The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety profile by eliminating excipients, polysorbate 80 and ethanol…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Columbus Regional Research Institute, LLC, Columbus, Georgia

    Locations

    4 in total

    Run by

    Jina Pharmaceuticals Inc.

    See if you can join NCT03671044 on ClinicalTrials.gov

12. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Curebase, San Francisco, California

    Run by

    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov

13. Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

    The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving c…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Harris Health System - Smith Clinic, Houston, Texas

    Locations

    2 in total

    Run by

    Baylor Breast Care Center

    See if you can join NCT05020860 on ClinicalTrials.gov

14. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

    This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    6 in total

    Run by

    Simcha IL-18, Inc.

    See if you can join NCT04787042 on ClinicalTrials.gov

15. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determ…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    3 in total

    Run by

    BioEclipse Therapeutics

    See if you can join NCT04282044 on ClinicalTrials.gov

16. A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

    A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Dallas, Dallas, Texas

    Locations

    2 in total

    Run by

    Hefei TG ImmunoPharma Co., Ltd.

    See if you can join NCT05746897 on ClinicalTrials.gov

17. First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

    This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. Th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

    Run by

    A&G Pharmaceutical Inc.

    See if you can join NCT05627960 on ClinicalTrials.gov

18. The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

    The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. Howev…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Baptist Health Clinical Research, Elizabethtown, Kentucky

    Run by

    VastBiome

    See if you can join NCT05037825 on ClinicalTrials.gov